Personally I’m invested to see the company develop at least one new patented drug. That won’t happen in January or February but the benchmark is GW Pharma, acquired for US $7.4 billion with one CBD based drug.
OSA could well be the first successful drug for IHL and it’s a multi billion dollar opportunity. Remember it’s the clinical programs that are driving shareholder value.
Achieving a US listing will expose the company to a more sophisticated market but it hardly matters if it happens this week. Some of the comments on this thread are so short sighted.
IHL Price at posting:
64.5¢ Sentiment: Buy Disclosure: Held
